NCT06353646 2026-02-13
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
Clinical Trials
7 trialsNCT05481476 2025-09-04
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06050317 2025-07-22
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05562297 2025-01-22
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06572813 2025-01-10
CISPD-7
Zhejiang University
Phase 1/2 Recruiting
NCT06761027 2025-01-07
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Fujian Provincial Hospital
Phase 1/2 Recruiting
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown